The Goal Is Not Clearance Alone. The Goal Is A Sellable Entry Point.
Getting to a lawful U.S. market-entry position is necessary. It is not the finish line.
After that, the company still has to sell.
That means the founder must understand:
This is not conference activity. It is not "we met many investors" or "we spoke with important people."
The harder, more useful work is usually quieter: talk to enough real target customers, test whether they understand the problem, test whether the buyer reason is real, and learn whether they are willing to leave their name, organization, role, and contact path for follow-up when the product can be sold.
That kind of demand signal does not replace regulatory work. It tells the founder whether the chosen market-entry path is connected to revenue.
The order matters.
If the founder asks the consultant to choose first, the consultant can only work from product documents, intended-use statements, public comparators, evidence, and experience. Those are important, but they are not the same as market feedback.
The consultant usually will not sit with target customers, test the message, watch what confuses them, learn which feature becomes a buying reason, or find out what makes a qualified buyer join a waiting list. That work belongs to the founder and the early commercial team.
Then the founder can return to the consultant with better questions:
That is the right sequence: founder tests the market logic, consultant evaluates the regulatory and evidence path, founder makes the decision.
Do not reduce this to "free trial means compliant." It does not. Any pilot, evaluation use, clinical use, patient-data collection, or device distribution before clearance or authorization needs qualified regulatory, legal, clinical, and quality review. But within the right boundary, the founder can still test problems, messages, buying reasons, workflow pain, qualified interest, and waiting-list demand.
- which similar products or alternatives already exist in the market;
- what those products taught buyers to expect;
- which features of the new device can become buyer buying reasons;
- which claims can be made inside the evidence and regulatory boundary;
- who the first reachable target customer is;
- whether the person who uses the device is also the person who buys, prescribes, recommends, or approves it;
- what message can be tested before clearance or authorization without overclaiming;
- what evidence of demand would matter: qualified conversations, letters of interest, pilot intent, or a waiting list that can be activated after the company is allowed to sell.
- "These are the target customers who responded."
- "This is the message they understood."
- "This is the buying reason that made them willing to stay in touch."
- "This is the use setting and claim boundary we think we can sell inside."
- "If we pursue this path, what product code, intended-use wording, evidence plan, cost, difficulty, and timeline should we expect?"
- "If that path is too expensive, too slow, or too difficult, what staged route preserves the buyer reason without overclaiming?"
The Route Label Is Not The Decision
"510(k)" is not a strategy.
"De Novo" is not a strategy.
"Q-Submission first" is not a strategy.
Those can be parts of a strategy, but they are not the whole thing.
The strategic question is what each path does to the company's first market step.
Ask what each path changes:
This is where a senior consultant earns trust. Not by giving the fastest answer, but by helping the founder see what the answer costs.
- What intended use can be supported?
- What claim boundary can the company live inside?
- What evidence is needed before submission or launch?
- What cost and timeline are realistic?
- What buyer problem can be explained without overclaiming?
- Which product features become buying reasons, and which remain only technical features?
- Who is the target customer: user, buyer, prescriber, department leader, procurement owner, distributor, or another influence point?
- What current alternative or comparator will the customer understand?
- What can the sales team say without creating future risk?
- What must wait until revenue, customer feedback, postmarket learning, or stronger evidence exists?
A Good Consultant Helps You Think In Stages
Most early medical-device companies cannot afford to solve the whole future at once.
They need first survival.
That usually means one focused market wedge:
This first wedge may be smaller than the founder's long-term vision. That is not failure. It can be discipline.
The danger is choosing a regulatory path as if the first submission must express the entire future company. That can push the team into broader claims, heavier evidence burden, slower timing, higher cost, and a sales story that may not be needed to get the first foothold.
The opposite danger is choosing the quickest route without understanding what it gives up. That can create a narrow or confusing market position, weak buyer reason, future relabeling pressure, or distributor language that drifts beyond the boundary.
A strong consultant helps the founder compare these options without pretending there is no tradeoff.
- one buyer or buyer group;
- one use setting;
- one evidence-supported claim boundary;
- one current alternative the customer already understands;
- one reason the customer would care now;
- one path to first revenue.
The Consultant Should Expose Five Layers
Before you choose the consultant, ask each candidate to explain their reasoning in five layers.
1. Confirmed Facts
What is actually known?
This includes the product description, intended use, user setting, current evidence, current labeling, public FDA records, comparable devices, available testing, known customer workflow, and current claims in the website, deck, manual, distributor material, or demo script.
If the fact can be tied to a source, record the source.
2. Reasonable Inference
What appears likely from the facts, but is not confirmed for this product?
This may include route hypotheses, product-code hypotheses, predicate or comparator hypotheses, evidence-gap hypotheses, and first market-position hypotheses.
These are useful. They are not facts.
3. Professional Judgment
Where is the consultant using experience?
Experienced judgment matters. It can help interpret ambiguous route signals, likely reviewer concerns, evidence expectations, Q-Submission value, and sequencing. But it should be labeled as judgment, not presented as certainty.
4. Risk Assumption
What risk does the company accept if it moves now?
For example:
These are founder and board decisions. They are not just consultant work product.
- accepting a narrower first claim;
- spending on testing before route clarity is stronger;
- delaying a broader claim until evidence improves;
- entering with a more conservative sales story;
- taking a staged route that supports revenue first and expansion later.
5. Next Validation Step
What is the smallest next action that reduces the most important uncertainty?
This may be a focused evidence review, a predicate comparison, a Q-Submission question set, a claim-boundary cleanup, a customer-workflow interview, a sales-material review, or a Product Identification (Product ID) intake that organizes the product facts, public sources, open questions, and decision memory around one product.
The Best Consultant Questions Are Commercial Too
The consultant does not need to become your chief marketing officer.
But the consultant's advice must not break the market strategy.
Ask:
This is not "marketing spin." It is decision discipline.
If a founder cannot explain the first buyer reason within the evidence-supported boundary, the company may get a technical answer and still fail commercially.
- If we follow this route, what can we credibly say to the first buyer?
- Which customer problem can be explained within this claim boundary?
- What product feature is tempting to sell but not yet supported?
- What current alternative should we compare against in customer language?
- What should not appear in the website, sales deck, distributor script, or training material yet?
- What evidence would let us expand the story later?
- What is the first revenue path this route preserves?
How To Compare Three Consultant Answers
Do not compare only price, timeline, or confidence.
Use a comparison map.
The winning consultant is not always the one with the most attractive column.
The winning consultant is the one whose reasoning lets the founder make a clearer decision.
- Route hypothesis: What path do they suggest?
- Evidence burden: What evidence do they believe is needed?
- Claim boundary: What can the company say first?
- Target customer: Who can be reached first: user, buyer, prescriber, department leader, procurement, distributor, or another influence point?
- Buying reason: Which device features become reasons to buy, and which remain only technical features?
- Sales consequence: Does this make the first buyer story easier or harder?
- Cost / timing: What work, fee, and delay does this imply?
- Assumptions: What are they assuming about product, user, comparator, evidence, or market?
- Demand test: What can be tested before clearance or authorization without overclaiming?
- Risk: What does the company accept if it follows this path?
- Next validation: What small action reduces the biggest uncertainty?
What to do before the next consultant call
Prepare a one-page founder packet:
- 1Product truth: what the device is, who uses it, where it is used, and what it does.
- 2Market map: similar products, current alternatives, possible product codes, visible claims, and customer expectations.
- 3Current claim boundary: what the company is saying now and what evidence supports it.
- 4First buyer reason: why one target customer would care enough to change behavior, budget, workflow, or trust.
- 5Buyer map: who uses, buys, prescribes, recommends, approves, or blocks adoption.
- 6Demand signal: which customer conversations, waiting-list commitments, pilot interest, or qualified follow-ups already exist.
- 7Evidence state: what exists, what is missing, and what is only assumed.
- 8Route hypotheses: what paths seem possible and why.
- 9Commercial pressure: investor, customer, distributor, launch, or first-revenue deadline.
- 10Decision question: what you need the consultant to help you decide now.
Source ledger
These sources are used to organize questions and public context. They do not make the final product-specific decision.
Can help establish
The Food and Drug Administration (FDA) describes broad United States market-entry steps including classification, submission selection / preparation, FDA interaction, and postmarket controls.
Cannot decide
A specific product's route, classification, consultant choice, commercial strategy, clearance, approval, safety, effectiveness, or compliance.
Can help establish
FDA describes the 510(k) substantial-equivalence concept, including comparison with legally marketed devices where the 510(k) pathway applies.
Cannot decide
Whether a specific product needs a 510(k), which predicate is suitable, or whether the product is substantially equivalent.
Can help establish
FDA provides mechanisms for submitters to request FDA feedback related to medical-device submissions.
Cannot decide
What FDA would say about a specific product or which questions a company should ask without product-specific review.
Can help establish
FDA describes eSTAR as a structured submission template and explains completeness expectations for most 510(k) and De Novo submissions.
Cannot decide
Whether a specific submission package is complete, sufficient, or acceptable.
Can help establish
The guide supports practical diligence questions about scope, similar experience, who does the work, current knowledge, references, and pricing.
Cannot decide
Whether a specific consultant is the right choice for a company or product.
FAQ
Can a consultant choose the right FDA path for the founder?
A consultant can evaluate regulatory pathways, evidence needs, claim boundaries, cost, difficulty, and timing. The founder still has to test target customers, buyer reasons, demand signals, and the market path the company can actually sell.
Can TrueMedDevice replace a regulatory consultant?
No. TrueMedDevice organizes product context, public evidence, open questions, customer-feedback notes, and decision memory so founders can have sharper conversations with qualified regulatory, legal, clinical, quality, and commercial reviewers.